Meat grown from animal cells rather than animals has been approved for sale in several jurisdictions and is available in limited quantities. The science works. The economics do not yet.
The cost problem
Growing cells requires a medium containing nutrients and growth factors, and the growth factors have historically been the expensive part – originally sourced from animal blood, now produced by other means at costs that have fallen sharply and remain far above what commodity meat requires.
Bioreactors are the other constraint. Producing meat at the scale of conventional agriculture would need fermentation capacity that does not exist, and building it is capital-intensive.
What has been achieved
Products that pass regulatory review as safe. Blended products, mixing cultivated cells with plant material, that reach a price consumers might pay. And steady declines in the cost of the inputs.
What has not
Whole cuts with the structure of muscle, which require scaffolding and vascularisation that are still research problems. Price parity with conventional meat, which remains distant. And any meaningful share of the meat market.
The political dimension
Several jurisdictions have banned cultivated meat pre-emptively, on grounds ranging from consumer protection to protecting existing agriculture. That is unusual for a food technology and reflects how much is at stake for the incumbent industry.
The realistic forecast
A premium niche for years, expanding as costs fall, with blended products leading. Not a replacement for conventional meat on any near timeline. Whether it becomes one depends on manufacturing scale that has to be built rather than discovered.